

DNA hypermethylation markers of poor outcome in laryngeal cancer

Josena K. Stephen · Kang Mei Chen · Veena Shah ·
Shaleta Havard · Alissa Kapke · Mei Lu ·
Michael S. Benninger · Maria J. Worsham

Received: 19 March 2010 / Accepted: 31 May 2010 / Published online: 24 June 2010
© Springer-Verlag 2010

Abstract This study examined molecular (DNA hypermethylation), clinical, histopathological, demographical, smoking, and alcohol variables to assess diagnosis (early versus late stage) and prognosis (survival) outcomes in a retrospective primary laryngeal squamous cell carcinoma (LSCC) cohort. The study cohort of 79 primary LSCC was drawn from a multi-ethnic (37% African American), primary care patient population, diagnosed by surgical biopsies in the Henry Ford Health System from 1991 to 2004 and followed from 5 to 18 years (through 2009). Of the 41 variables, univariate risk factors of $p < 0.10$ were tested in multivariate models (logistic regression (diagnosis) and Cox (survival) models ($p < 0.05$)). Aberrant methylation of estrogen receptor 1 (*ESR1*; $p = 0.01$), race as African American ($p = 0.04$), and tumor necrosis

(extensive; $p = 0.02$) were independent predictors of late stage LSCC. Independent predictors of poor survival included presence of vascular invasion ($p = 0.0009$), late stage disease ($p = 0.03$), and methylation of the hypermethylated in cancer 1 (*HIC1*) gene ($p = 0.0002$). Aberrant methylation of *ESR1* and *HIC1* signified independent markers of poorer outcome. In this multi-ethnic, primary LSCC cohort, race remained a predictor of late stage disease supporting disparate diagnosis outcomes for African American patients with LSCC.

Keywords Laryngeal cancer · Hypermethylation · *ESR1* · *HIC1*

Introduction

Laryngeal cancer represents the largest subgroup of head and neck cancers (Clayman et al. 2000). Roughly 12,250 new cases of laryngeal cancer are diagnosed each year in the USA (Horner et al. 2009). Given the fundamental role the larynx plays in human speech and communication, determining the optimal management of laryngeal cancers is critical. Treatment options comprise radiotherapy, surgery, chemotherapy or a combination of modalities. Despite refinement of multimodal therapies over the last 20 years, 5-year survival rates of 40% have remained static since the mid-1980s (Parkin et al. 2001).

Although the importance of genetic alterations in cancer has long been recognized, the appreciation of epigenetic changes is more recent and growing. The term “epigenetics” defines all meiotically and mitotically heritable changes in gene expression that are not coded in the DNA sequence itself (Egger et al. 2004). Establishment and maintenance of

J. K. Stephen · K. M. Chen · S. Havard · M. J. Worsham (✉)
Department of Otolaryngology/Head and Neck Surgery,
Henry Ford Hospital,
1 Ford Place, 1D,
Detroit, MI 48202, USA
e-mail: mworshal@hfhs.org

V. Shah
Department of Pathology,
Henry Ford Hospital,
1 Ford Place, 1D,
Detroit, MI 48202, USA

A. Kapke · M. Lu
Department of Biostatistics and Research Epidemiology,
Henry Ford Hospital,
Detroit, MI 48202, USA

M. S. Benninger
Head and Neck Institute, Cleveland Clinic,
Cleveland, OH 44195, USA

epigenetic control (gene silencing) has several aspects, which include promoter region hypermethylation, methyl-binding proteins, DNA methyltransferases (DNMTs), histone deacetylases (HDAC), and chromatin state.

DNMTs are enzymes that catalyze the methyl-transfer reaction. Global cytosine methylation patterns in mammals appear to be established by an interplay of three DNMTs: DNMT1, DNMT3A, and DNMT3B. The role of DNMTs is evolving from mere enzymes that copy methylation patterns after replication to being regarded as components of larger complexes actively involved in transcriptional control and chromatin structure modulation (Robertson 2001).

In addition to DNMTs, HDACs play a role in repressing DNA transcription. The HDACs deacetylate core histone tails resulting in tighter packaging of the DNA, making it difficult for transcription factors to access their binding sites (Robertson and Wolffe 2000). Following DNA methylation, methyl-CpG-binding proteins are recruited along with HDACs. This link between DNA methylation and histone deacetylation has been demonstrated by treating cells with a combination of the DNMT inhibitor 5-aza-2'-deoxycytidine (5-azaCdR) and the HDAC inhibitor trichostatin A (TSA). Treatment with 5-azaCdR alone resulted in low-levels of re-expression and minimal demethylation of hypermethylated genes, but a combination of 5-azaCdR and TSA resulted in robust activation of the same genes (Cameron et al. 1999), revealing that DNA methylation and histone deacetylation work together to silence transcription but also that DNA methylation was dominant over histone acetylation status.

Hypermethylation is a well-described DNA modification that has been implicated in normal mammalian development (Costello and Plass 2001; Li et al. 1992), imprinting (Li et al. 1993), and X chromosome inactivation (Pfeifer et al. 1990). CpG islands, which are stretches of DNA with a GC content greater than 55% (Takai and Jones 2002) located in promoter regions of genes, are mainly unmethylated in normal tissues. Methylation of these CpG islands causes stable heritable transcriptional silencing (Egger et al. 2004). This anomalous hypermethylation has been noted in a variety of tumor-suppressor genes, whose inactivation has led many cells down the tumorigenesis continuum (Jones and Laird 1999; Baylin et al. 1998; Chan et al. 2000). Aberrant methylation of CpG islands is a hallmark of human cancers and is found early during carcinogenesis (Egger et al. 2004). Numerous tumor-suppressor genes have been implicated as targets for methylation in other cancers (Cairns 2004; Kim et al. 2004; Roman-Gomez et al. 2004). Promoter hypermethylation of genes in HNSCC have been reported for *p16*, *p14*, *DAPK*, *RASSF1A*, *RARβ2*, *MGMT*, a DNA repair gene that functions to remove mutagenic (O^6 -guanine) adducts from DNA, and *E-cadherin*, a Ca^{2+} -dependent cell adhesion molecule that functions in cell–cell adhesion, cell polarity, and morpho-

genesis (Esteller et al. 2001; Sanchez-Cespedes et al. 2000; Worsham et al. 2006; Zou et al. 2001; Pegg 1990; Hirohashi 1998).

Molecular and genetic prognosticators have been shown to play a role in the prevention, diagnosis, radiotherapy outcomes, and appropriateness of adjuvant chemotherapy for a wide spectrum of cancers (Lazarus et al. 1996), including laryngeal squamous cell carcinoma (LSCC). Diagnosis, prognosis, and treatment of these malignancies are expected to be greatly enhanced by the identification of tumor markers specific for LSCC.

Prognostic marker systems based on single parameters have generally proven inadequate. This study incorporated a multi-parametric platform comprising molecular (DNA hypermethylation), clinical, histopathological, demographical, and epidemiological risk variables including smoking and alcohol to model diagnosis (early versus late stage) and prognosis (survival) outcomes in LSCC.

Materials and methods

Cohort

The retrospective study cohort of 79 primary LSCC was examined for a comprehensive set of 41 variables to include eight histopathology factors (Sethi et al. 2009): tumor grade (well, moderate, and poorly differentiated), lymphocytic response (continuous rim/patchy infiltrate/absent), desmoplastic response (prominent and diffuse/patchy and irregular/focal/absent), pattern of invasion (host/tumor interface with pushing cohesive borders (mode 1)/solid cords (mode 2)/thin irregular cords(mode 3)/single cells(mode 4)), vascular invasion (identified/absent), perineural invasion (identified/absent), mitotic index (<5 mitosis per ten high power fields (HPF) and >5 mitosis per ten HPF), and necrosis (extensive/minimal/absent); demographics (four variables: race (as self-reported), gender, age, and marital status); clinical factors (three variables: comorbidity, pneumonia, and family history of cancer); smoking and alcohol; and promoter methylation status of 24 tumor-suppressor genes.

Patient tissue material for this study was obtained according to the Henry Ford Health System institutional review board protocols.

DNA extraction

Whole 5- μ m tissue sections or microdissected LSCC lesions and adjacent normal when present were processed for DNA extraction as previously described (Stephen et al. 2007).

Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay

Archival tissue DNA was interrogated for methylation status using the multi-gene methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. MS-MLPA (Worsham et al. 2006; Chen et al. 2007), a modification of the conventional MLPA assay (Schouten et al. 2002), allows for the simultaneous detection of changes in methylation status as well as copy number changes of approximately 41 different DNA sequences in a single reaction requiring only 20 ng of human DNA.

Briefly, the MS-MLPA panel in the presence of HhaI detects aberrant promoter hypermethylation by taking advantage of an HhaI site in the gene probe of interest. The control gene probes, without an HhaI site, serve as undigested controls. A normal control DNA sample will generate 41 individual peaks for all probes in the absence of HhaI and 15 separate peaks in the presence of HhaI (Fig. 1). Normal controls for methylation assays are run using DNA from paraffin-embedded squamous epithelium from individuals with no evidence of cancer.

Gene probe panels

The 41 gene probe panel (ME001B, www.mlpa.com) used in this cohort interrogates 38 unique genes (24 tumor-suppressor genes) implicated in squamous head and neck cancer (HNSCC) for methylation status in two separate reactions (one in the absence of the methyl-sensitive enzyme HhaI and one in the presence of the HhaI enzyme). There are two probes each for *MLH1*, *RASSF1*, and *BRCA2*, and a normal control DNA sample will generate 41 individual peaks in the absence of HhaI and 15 individual peaks in the presence of HhaI (Fig. 1).

Data analysis


Logistic regression and Cox regression models were used to determine risk factors for diagnosis (early vs. late stage) and for prognosis (survival), respectively. Univariate analysis was followed by multivariable modeling. Variables with $p < 0.10$ in the univariate analysis were tested as independent predictors in the multivariable modeling process. The final multivariate logistic regression (diagnosis) and Cox (survival) models included variables with $p < 0.05$. In order to address the issue of multiple comparisons, the multivariable stage model was selected by following the ten observations/events for each variable guideline (Harrell et al. 1984). Kaplan–Meier curves were generated to illustrate survival outcomes for independent risk factors.

Results

Of the 79 primary LSCC, 45 were Caucasian American (CA), 32 (41%) were African American (AA), and 2 were other race; 38 were with early stage, 40 late stage, and 1 unknown stage. There were 59 males and 20 females. Other cohort characteristics including age, smoking status, and alcohol use are presented in Table 1.

Of the 24 tumor-suppressor genes, 17 were aberrantly methylated in at least one case to include *TIMP3*, *APC*, *CDKN2A*, *MLH1*, *RARB*, *CDKN2B*, hypermethylated in cancer 1 (*HIC1*), *CHFR*, *BRCA2*, *RASSF1*, *DAPK1*, estrogen receptor 1 (*ESR1*), *TP73*, *IGSF4*, *CDH13*, *GSTP1*, and *CDKN1B*. The most frequently methylated genes were *GSTP1* (34/79), *CDH13* (27/79), *TP73* (18/79), *RARB* (17/79), *APC* (13/79), *CHFR* (12/79), *DAPK1* (11/79), *CDKN2A*, and *ESR1* (10/79).

a Normal



b Case 78




Fig. 1 **a** A normal control DNA sample generates 41 individual peaks for all probes in the absence of HhaI (red) and 15 separate peaks in the presence of HhaI (blue). **b** Aberrant methylation

identified in tumor sample as the appearance of a signal peak that is otherwise absent in normal DNA samples, seen here for *APC*, *CHFR*, *DAPK1*, and *ESR1*

Table 1 Cohort characteristics

Variable	Response	Early stage, N=38	Late stage, N=40	Unknown stage, N=1
Race	African American	11	20	1
	Caucasian American	27	18	–
	Other	–	2	–
Gender	Male	29	29	1
	Female	9	11	–
Age	Less than 50 years	18	16	1
	51–65 years	14	17	–
	Over 65 years	6	7	–
Smoking	Current smoker	21	26	1
	Past smoker	16	11	–
	Never smoker	1	3	–
Alcohol use ^a	No	1	1	–
	Yes	31	35	1

^aMissing for ten LSCC

Four variables, *ESR1*, *APC*, tumor necrosis, and race, with univariate effects for late stage ($p < 0.10$) were included in the first multivariable model. After modeling, aberrant methylation of *ESR1* ($p = 0.014$, OR = 16.35; 95% CI, 1.75, 152.5), race ($p = 0.035$, OR = 3.17; 95% CI, 1.08, 9.26), and extensive tumor necrosis ($p = 0.018$, OR = 5.15; 95% CI, 1.33, 20.01) remained in the final model as independent predictors of late stage LSCC (Table 2). The area under the curve, a measure of the model's predictive ability, was 0.78.

The median survival for patients in this cohort was 4.40 years (range, 0.04 to 16.21). Five variables, *HIC1*, *DAPK1*, vascular invasion, comorbidity, and stage, with individual effects ($p < 0.10$) for poor survival were included in the initial multivariable model. The final multivariate survival (Otterson et al. 1995) model indicated vascular invasion ($p = 0.0009$, HR = 4.51; 95% CI, 1.86, 10.93), late stage disease ($p = 0.029$, HR = 2.16; 95% CI, 1.08, 4.32), and methylation of the *HIC1* gene ($p = 0.0002$, HR = 9.52; 95% CI, 2.92, 31.01) as independent predictors of poor survival (Table 3). Kaplan–Meier curves, generated for each risk variable retained in the final multivariable model, are illustrated in Figs. 2, 3, and 4. LSCC patients with vascular invasion ($n = 8$, adjusted $p < 0.01$) had a significantly shorter survival time as compared to patients without vascular invasion ($n = 69$, Fig. 2). LSCC patients with late stage disease ($n = 40$, stages 3 and 4, adjusted $p = 0.029$) had poorer survival as compared to those with early stage disease ($n = 38$, stages 0, 1, and 2, Fig. 3). LSCC patients without *HIC1* methylation ($n = 74$) had a median survival of

4.40 (range, 0.04 to 16.21) as compared to a median survival of 1.02 years (range, 0.044 to 2.88) for patients with *HIC1* methylation ($n = 5$, adjusted $p < 0.01$, Fig. 4).

Discussion

Epigenetic mechanisms involve DNA and histone modifications resulting in the heritable silencing of genes without a change in their coding sequence. The major form of epigenetic information in mammalian cells is DNA methylation, or the covalent addition of a methyl group to the fifth position of cytosine within CpG dinucleotide predominantly located in the promoter region, which normally remains unmethylated in normal cells (Jones and Laird 1999; Baylin et al. 1998). The consequence of CpG island hypermethylation, especially for those islands associated with tumor-suppressor gene promoters, is the loss of tumor-suppressor gene function, which contributes to tumorigenesis (Worsham et al. 2003). Gene silencing, as a consequence of promoter hypermethylation, can be partially relieved by demethylation of the promoter region (Jones and Laird 1999; Baylin and Herman 2000). Recent work has revealed that DNA methylation is an important player in many processes, including DNA repair, genome instability, and regulation of chromatin structure (Jones and Laird 1999; Jones and Baylin 2002).

Promoter methylation-mediated silencing is a hallmark of many established tumor-suppressor genes. Aberrant

Table 2 Multivariable stage model

Variable	OR	95% confidence limits	<i>p</i> value	
<i>ESR1</i> : methylation vs no methylation	16.35	1.75	152.5	0.014
Tumor necrosis: extensive vs none	5.15	1.33	20.01	0.018
Race: African American vs Caucasian American	3.17	1.08	9.26	0.035

Table 3 Multivariable survival model

Variable	Hazard ratio	95% confidence limits		p value
Stage: late vs early	2.16	1.08	4.32	0.029
<i>HIC1</i> : methylation vs no methylation	9.52	2.92	31.01	0.0002
Vascular invasion: identified vs not identified	4.51	1.86	10.93	0.0009

methylation of promoter CpG islands, as an alternative to gene mutation or deletion in tumorigenesis, is now recognized as an important mechanism for gene inactivation (Baylin et al. 1998). Previous studies from our group and others have demonstrated aberrant DNA methylation patterns in HNSCC, underscoring a role for epigenetics in tumor pathogenesis.

Genes found to be methylated in LSCC and HNSCC include *CDKN2A*, *CDKN2B*, *DAPK1*, *IGSF2*, *MLH1*, and *RBI*. Inactivation of the *CDKN2B/p15*, *CDKN2A/p14*, and *CDKN2A/p16* genes is a frequent event in human oral squamous cell carcinomas (Worsham et al. 2006; Shintani et al. 2001). The presence of aberrant methylation of p15 and p16 in precancerous oral tissues (Shintani et al. 2001) implicates methylation of p15 and p16 as early events in the pathogenesis of oral lesions.

Aberrant promoter methylation of *DAPK1* has been shown to frequently occur in human head and neck cancers (Worsham et al. 2006; Sanchez-Cespedes et al. 2000), non-small-cell lung carcinomas (Esteller et al. 1999), gastric and colorectal carcinomas (Lee et al. 2002; Satoh et al. 2002), and uterine cervical carcinomas (Dong et al. 2001). In HNSCC, *DAPK1* promoter hypermethylation has been associated with metastasis to lymph nodes as well as advanced disease stage (Sanchez-Cespedes et al. 2000). Promoter hypermethylation

of *IGSF2*, a novel immunoglobulin-like intercellular adhesion molecule first characterized as a tumor suppressor of non-small cell lung cancer and termed *TSLC1* (Kuramochi et al. 2001), has been reported in nasopharyngeal carcinomas (Hui et al. 2003). In esophageal squamous cell carcinomas, loss of expression correlated with promoter methylation status and *TSLC1* expression was restored by demethylating agents in cell lines (Ito et al. 2003).

MLH1 belongs to the group of genes controlling mismatch repair (Arzimanoglou et al. 2002), and its frequent methylation in dysplastic lesions of HNSCC samples indicates *MLH1* methylation as an early event in HNSCC tumorigenesis (Ghosh et al. 2010). *RBI* plays an important role in cell cycle control (RB pathway) (Sherr 1996; Yokoyama et al. 1996). *RBI* has been found to be methylated in oral squamous cell cancers, where it is highly correlated with tobacco use and/or alcohol consumption (Malekzadeh et al. 2009).

In this LSCC cohort, aberrant methylation of *ESR1* and *HIC1* was an independent predictor of late stage diagnosis and poorer survival outcomes, respectively. *ESR1*, at 6q25.1, is important for hormone binding, DNA binding, and activation of transcription (Ponglikitmongkol et al. 1988). *ESR1* has metastasis-suppressor properties, suggesting a tumor-suppressor role for *ESR1* (Issa et al. 1994).

Fig. 2 Patients with vascular invasion ($n=8$) had a significantly shorter survival time as compared to patients without vascular invasion ($n=69$)






Fig. 3 Patients with late stage disease ($n=40$, stage 3 and 4) had poorer survival as compared to those with early stage disease ($n=38$, stage 0, 1, and 2)



Methylation of CpG sites in the *ESR1* promoter, with concordant loss or downregulation of *ESR1* expression, is the primary mechanism in prostate cancer (Li et al. 2000). *ESR1* exhibits age-dependent methylation in colon mucosa (Issa et al. 1994), the cardiovascular system (Post et al. 1999), ulcerative colitis (Issa et al. 2001), and prostate cancer, suggesting that *ESR1* may be involved in age-dependent increase in cancer incidence.

Epigenetic silencing of *HIC1* has been shown to significantly influence tumorigenesis (Rathi et al. 2003). The underlying mechanism is via *HIC1*'s regulation of p53-dependent apoptotic DNA-damage responses through the HIC1-SIRT1-p53 circular loop (Chen et al. 2004). *HIC1* encodes a transcriptional repressor with five Kruppel-like C2H2 zinc finger motifs and an N-terminal BTB/POZ domain (Wales et al. 1995). SIRT1 is an NAD⁺-dependent

Fig. 4 Methylation of *HIC1* was an independent predictor of poorer survival. LSCC patients without *HIC1* methylation ($n=74$) had a median survival of 4.40 (range, 0.04 to 16.21) as compared to a median survival of 1.02 years (range, 0.044 to 2.88) for patients ($n=5$) with *HIC1* methylation



deacetylase, which is important for chromatin silencing, gene regulation, metabolism, and longevity (Haigis and Guarente 2006) and is a direct target of *HIC1* via the POZ domain (Chen et al. 2005). Under normal physiological conditions, actively expressed *HIC1* represses *SIRT1* transcription, thereby allowing acetylation of p53 to enhance its function to control growth arrest and apoptosis in response to stress, such as DNA damage (Chen et al. 2004). During the course of aging, the *HIC1* promoter undergoes hypermethylation, and this could set up transcriptional silencing of *HIC1* and release its repressive effects on *SIRT1* resulting in deacetylation of core histone and non-histone (p53) proteins. Chronic p53 deacetylation would attenuate its ability to transactivate or repress the expression of its downstream target genes for growth arrest and apoptosis, allowing cells to bypass these events and survive DNA damage (Chen et al. 2004). Deregulation of *HIC1*-*SIRT1*-p53 is a potential prognostic biomarker in lung cancer (Tseng et al. 2009). In pediatric tumor cell lines with aberrantly methylated *HIC1*, re-expression of *HIC1* mRNA was induced by treatment with demethylating agent 5-aza 2' deoxycytidine (Moscow et al. 1988).

In this cohort, survival of the five LSCC patients with *HIC1* methylation of less than 3 years was remarkably poorer when compared to those without *HIC1* methylation (Fig. 4). LSCC patients without *HIC1* methylation ($n=74$) had a median survival of 4.40 (range, 0.04 to 16.21) as compared to a median survival of 1.02 years (range, 0.044 to 2.88) for patients with *HIC1* methylation. As an independent predictor of poor survival in this LSCC cohort, an aberrantly methylated *HIC1* gene suggests a potential demethylating therapeutic target.

The most frequently methylated genes in this study cohort were *GSTP1* (34/79), *CDH13* (27/79), *TP73* (18/79), *RARB* (17/79), *APC* (13/79), and *CHFR* (12/79) and underscore their involvement in the pathogenesis of LSCC.

Glutathione S-transferase pi (*GSTP1*) encodes for the glutathione S-transferase pi enzyme which plays an important role in detoxification. Promoter hypermethylation pattern of the *p16*, *MGMT*, *GSTP1*, and *DAPK* genes have been used as molecular markers for cancer cell detection in the paired serum DNA, and almost half of the HNSCC patients with methylated tumors were found to display these epigenetic changes in the paired serum (Sanchez-Cespedes et al. 2000).

Aberrant methylation of *CDH13* gene was reported in colorectal, breast, lung cancers, and as a primary event in HNSCC cell lines (Worsham et al. 2006). In its tumor suppressor role of maintaining cell adhesion integrity, methylation-mediated silencing of *CDH13* would allow tumor cells to spread, facilitating metastasis and poorer survival.

TP73 codes a product which has significant structural homology to the *TP53* gene product in the domains involving transactivation, DNA binding, and oligomeriza-

tion (Dong et al. 2002). In HNSCC, hypermethylation of *TP73* occurred as a primary as well as a disease progression event (Worsham et al. 2006).

Promoter hypermethylation of *APC* has been reported in 25% of oral cancers (Uesugi et al. 2005). Aberrant promoter methylation of *APC* and *RARB* in early and late stage HNSCC suggests these occur as earlier epigenetic events when compared to methylation of *CHFR* (Chen et al. 2007). In this LSCC cohort, *CHFR* methylation occurred in eight early and four late stage tumors and, unlike *HIC1*, did not emerge as an independent predictor of late stage disease.

A current shortcoming in the more rigorous analysis of racial disparities in HNSCC is a dearth of study cohorts with adequate representation of minority patients. In this LSCC cohort, with 41% AA patient representation, AA were more likely to have advanced stage disease than their CA counterparts, and this is consistent with previous HNSCC studies from our group (Sethi et al. 2009).

There is substantial evidence that lack of adequate health insurance coverage is associated with less access to care and poorer outcomes for cancer patients (Ward et al. 2008), supporting insurance and cost-related barriers to high-quality prevention, early detection, and treatment as important measures to assess cancer disparities. Patients in this study cohort were primary LSCC within a primary health care setting. Of the 79 LSCC, insurance status was available in 69 (missing in 10/79), and only 1/69 lacked insurance, presenting a limitation of this variable in data analyses outcomes for this cohort.

Tumor behavior is dependent on a complex interrelationship between the tumor and patient (Sethi et al. 2009), and several studies have suggested expansion of the current TNM staging system to include host factors to augment the clinical utility and progress in cancer staging. In the present study, we evaluated the association of a broad spectrum of tumor histopathology characteristics at primary diagnosis in a diverse primary care LSCC cohort. Extensive tumor necrosis ($p=0.018$) was an independent predictor of late stage disease and concurs with a highly significant association of necrosis and higher node-positive disease in HNSCC (Kuhnt et al. 2005).

Vascular invasion has been significantly correlated with cancers of the floor of the mouth (Suzuki et al. 2007), but there is a lack of information with respect to vascular invasion and LSCC. In this cohort, presence of vascular invasion ($p=0.0009$) was a predictor of poor survival.

Smoking and alcohol abuse are well-established risk factors for LSCC (Hashibe et al. 2007). In this study cohort, the majority of patients were either current or past smokers (75/79) and alcohol users (67/69), reiterating the role of these risk factors in the pathogenesis of LSCC.

Epigenetic events of promoter hypermethylation are emerging as promising molecular targets for cancer detection

and represent an important tumor-specific marker in tumorigenesis. Aberrant methylation of *ESR1* and *HIC1* were independent predictors of late stage LSCC and poorer survival, respectively. A limitation of this study remains the relatively small number of patient samples and its retrospective analysis. Validation of these findings in larger LSCC cohorts would further support these genes as important DNA methylation markers with a role in treatment given the reversible nature of promoter methylation-associated gene silencing. Race remained a predictor of late stage disease supporting disparate diagnosis outcomes for African American patients with LSCC.

Acknowledgements Drs. Stephen and Worsham had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

This study was supported by R01 NIH DE 15990 (Dr. Worsham).

Conflict of interest The authors declare that they have no conflict of interest.

References

- Arzimanoglou II, Hansen LL, Chong D, Li Z, Psaroudi MC, Dimitrakakis C, Jacovina AT, Shevchuk M, Reid L, Hajjar KA, Vassilaros S, Michalas S, Gilbert F, Chervenak FA, Barber HR (2002) Frequent LOH at hMLH1, a highly variable SNP in hMSH3, and negligible coding instability in ovarian cancer. *Anticancer Res* 22(2A):969–975
- Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. *Trends Genet* 16(4):168–174
- Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. *Adv Cancer Res* 72:141–196
- Cairns P (2004) Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. *Ann N Y Acad Sci* 1022:40–43
- Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. *Nat Genet* 21(1):103–107
- Chan MF, Liang G, Jones PA (2000) Relationship between transcription and DNA methylation. *Curr Top Microbiol Immunol* 249:75–86
- Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB (2004) Epigenetic and genetic loss of *hic1* function accentuates the role of *p53* in tumorigenesis. *Cancer Cell* 6(4):387–398
- Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB (2005) Tumor suppressor *hic1* directly regulates *sirt1* to modulate *p53*-dependent DNA-damage responses. *Cell* 123(3):437–448
- Chen K, Sawhney R, Khan M, Benninger MS, Hou Z, Sethi S, Stephen JK, Worsham MJ (2007) Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 133(11):1131–1138
- Clayman GL, Lippman SM, Laramore GF et al (2000) Neoplasms of the head and neck. *Cancer medicine*, 5th edn. BC Becker Inc, New York (section 27)
- Costello JF, Plass C (2001) Methylation matters. *J Med Genet* 38(5):285–303
- Dong SM, Kim HS, Rha SH, Sidransky D (2001) Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. *Clin Cancer Res* 7(7):1982–1986
- Dong S, Pang JC, Hu J, Zhou LF, Ng HK (2002) Transcriptional inactivation of *tp73* expression in oligodendroglial tumors. *Int J Cancer* 98(3):370–375
- Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. *Nature* 429(6990):457–463
- Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. *Cancer Res* 59(1):67–70
- Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. *Cancer Res* 61(8):3225–3229
- Ghosh A, Ghosh S, Maiti GP, Sabbir MG, Zabarovsky ER, Roy A, Roychoudhury S, Panda CK (2010) Frequent alterations of the candidate genes *hmlh1*, *itga9* and *rbp3* in early dysplastic lesions of head and neck: clinical and prognostic significance. *Cancer Sci* 101(6):1511–1520
- Hagis MC, Guarente LP (2006) Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. *Genes Dev* 20:2913–2921
- Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA (1984) Regression modelling strategies for improved prognostic prediction. *Stat Med* 3(2):143–152
- Hashibe M, Boffetta P, Zaridze D, Shagina O, Szeszenia-Dabrowska N, Mates D, Fabianova E, Rudnai P, Brennan P (2007) Contribution of tobacco and alcohol to the high rates of squamous cell carcinoma of the supraglottis and glottis in Central Europe. *Am J Epidemiol* 165(7):814–820
- Hirohashi S (1998) Inactivation of the e-cadherin-mediated cell adhesion system in human cancers. *Am J Pathol* 153(2):333–339
- Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlander N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (2009) Seer cancer statistics review, 1975–2006. National Cancer Institute, Bethesda
- Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP (2003) Epigenetic inactivation of *tsl1* gene in nasopharyngeal carcinoma. *Mol Carcinog* 38(4):170–178
- Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB (1994) Methylation of the oestrogen receptor *cpg* island links ageing and neoplasia in human colon. *Nat Genet* 7(4):536–540
- Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA (2001) Accelerated age-related *cpg* island methylation in ulcerative colitis. *Cancer Res* 61:3573–3577
- Ito T, Shimada Y, Hashimoto Y, Kaganoji J, Kan T, Watanabe G, Murakami Y, Imamura M (2003) Involvement of *tsl1* in progression of esophageal squamous cell carcinoma. *Cancer Res* 63(19):6320–6326
- Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 3(6):415–428
- Jones PA, Laird PW (1999) Cancer epigenetics comes of age. *Nat Genet* 21(2):163–167
- Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, Han J, Park J, Kim DH (2004) Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. *J Clin Oncol* 22(12):2363–2370
- Kuhnt T, Mueller AC, Pelz T, Haensgen G, Bloching M, Koesling S, Schubert J, Dunst J (2005) Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy. *J Cancer Res Clin Oncol* 131(11):758–764
- Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH, Murakami Y (2001) *Tsl1* is a tumor-

- suppressor gene in human non-small-cell lung cancer. *Nat Genet* 27(4):427–430
- Lazarus CL, Logemann JA, Pauloski BR, Colangelo LA, Kahrilas PJ, Mittal BB, Pierce M (1996) Swallowing disorders in head and neck cancer patients treated with radiotherapy and adjuvant chemotherapy. *Laryngoscope* 106(9 Pt 1):1157–1166
- Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF (2002) Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. *Clin Cancer Res* 8(6):1761–1766
- Li E, Bestor TH, Jaenisch R (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* 69(6):915–926
- Li E, Beard C, Jaenisch R (1993) Role for DNA methylation in genomic imprinting. *Nature* 366(6453):362–365
- Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R (2000) Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. *Cancer Res* 60:702–706
- Malekzadeh K, Sobti RC, Nikbakht M, Shekari M, Hosseini SA, Tamandani DK, Singh SK (2009) Methylation patterns of *rb1* and *casp-8* promoters and their impact on their expression in bladder cancer. *Cancer Invest* 27(1):70–80
- Moscow JA, Townsend AJ, Goldsmith ME, Whang-Peng J, Vickers PJ, Poisson R, Legault-Poisson S, Myers CE, Cowan KH (1988) Isolation of the human anionic glutathione s-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. *Proc Natl Acad Sci U S A* 85(17):6518–6522
- Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ (1995) *Cdkn2* gene silencing in lung cancer by DNA hypermethylation and kinetics of p16ink4 protein induction by 5-aza 2'deoxyctidine. *Oncogene* 11(6):1211–1216
- Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 94(2):153–156
- Pegg AE (1990) Mammalian O⁶-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. *Cancer Res* 50(19):6119–6129
- Pfeifer GP, Tanguay RL, Steigerwald SD, Riggs AD (1990) In vivo footprint and methylation analysis by PCR-aided genomic sequencing: comparison of active and inactive X chromosomal DNA at the CpG island and promoter of human *pgk-1*. *Genes Dev* 4(8):1277–1287
- Ponglikitmongkol M, Green S, Chambon P (1988) Genomic organization of the human oestrogen receptor gene. *EMBO J* 7(11):3385–3388
- Post WS, Goldschmidt-Clermont PJ, Wilhide CC, Heldman AW, Sussman MS, Ouyang P, Milliken EE, Issa JP (1999) Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. *Cardiovasc Res* 43:985–991
- Rathi A, Virmani AK, Harada K, Timmons CF, Miyajima K, Hay RJ, Mastrangelo D, Maitra A, Tomlinson GE, Gazdar AF (2003) Aberrant methylation of the *h1c1* promoter is a frequent event in specific pediatric neoplasms. *Clin Cancer Res* 9(10 Pt 1):3674–3678
- Robertson KD (2001) DNA methylation, methyltransferases, and cancer. *Oncogene* 20:3139–3155
- Robertson KD, Wolffe AP (2000) DNA methylation in health and disease. *Nat Rev Genet* 1(1):11–19
- Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A, Torres A (2004) Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. *Blood* 104(8):2492–2498
- Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. *Cancer Res* 60(4):892–895
- Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y, Suzuki H, Yawata A, Kusano M, Fujita M, Hosokawa M, Yanagihara K, Tokino T, Imai K (2002) DNA methylation and histone deacetylation associated with silencing *dap* kinase gene expression in colorectal and gastric cancers. *Br J Cancer* 86(11):1817–1823
- Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res* 30(12):e57
- Sethi S, Lu M, Kapke A, Benninger MS, Worsham MJ (2009) Patient and tumor factors at diagnosis in a multi-ethnic primary head and neck squamous cell carcinoma cohort. *J Surg Oncol* 99(2):104–108
- Sherr CJ (1996) Cancer cell cycles. *Sciences* 274:1672–1677
- Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T (2001) Inactivation of the *p14(arf)*, *p15(ink4b)* and *p16(ink4a)* genes is a frequent event in human oral squamous cell carcinomas. *Oral Oncol* 37(6):498–504
- Stephen JK, Vaught LE, Chen KM, Shah V, Schweitzer VG, Gardner G, Benninger MS, Worsham MJ (2007) An epigenetically derived monoclonal origin for recurrent respiratory papillomatosis. *Arch Otolaryngol Head Neck Surg* 133(7):684–692
- Suzuki M, Suzuki T, Asai M, Ichimura K, Nibu K, Sugawara M, Kaga K (2007) Clinicopathological factors related to cervical lymph node metastasis in a patient with carcinoma of the oral floor. *Acta Otolaryngol Suppl* 559:129–135
- Takai D, Jones PA (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. *Proc Natl Acad Sci U S A* 99(6):3740–3745
- Tseng R, Lee C, Hsu H, Tzao C, Wang Y (2009) Distinct *h1c1-sirt1-p53* loop deregulation in lung squamous carcinoma and adenocarcinoma patients. *Neoplasia* 11(8):763–770
- Uesugi H, Uzawa K, Kawasaki K, Shimada K, Moriya T, Tada A, Shiiba M, Tanzawa H (2005) Status of reduced expression and hypermethylation of the *apc* tumor suppressor gene in human oral squamous cell carcinoma. *Int J Mol Med* 15(4):597–602
- Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB (1995) P53 activates expression of *h1c1*, a new candidate tumour suppressor gene on 17p13.3. *Nat Med* 1(6):570–577
- Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A (2008) Association of insurance with cancer care utilization and outcomes. *CA Cancer J Clin* 58(1):9–31
- Worsham MJ, Pals G, Schouten JP, Van Spaendonck RM, Concus A, Carey TE, Benninger MS (2003) Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 129(7):702–708
- Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP, Benninger MS (2006) Epigenetic events of disease progression in head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 132(6):668–677
- Yokoyama J, Shiga K, Sasano H, Suzuki M, Takasaka T (1996) Abnormalities and the implication of retinoblastoma locus and its protein product in head and neck cancers. *Anticancer Res* 16:641–644
- Zou CP, Youssef EM, Zou CC, Carey TE, Lotan R (2001) Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor *rar beta* and on retinoid resistance in human squamous carcinoma cells. *Oncogene* 20(47):6820–6827